Reposal

Reposal
Clinical data
Other names	Reposamal, 5-Ethyl-5-(bicyclo(3.2.1)octenyl)barbituric acid
ATC code	N05CA12 (WHO) ;
Identifiers
	IUPAC name 5-bicyclo[3.2.1]oct-2-en-3-yl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione;
CAS Number	3625-25-0 ;
PubChem CID	19254;
ChemSpider	10468690 ;
UNII	3T5TIX1AYI;
ChEMBL	ChEMBL505851 ;
CompTox Dashboard (EPA)	DTXSID50877567 ;
Chemical and physical data
Formula	C14H18N2O3
Molar mass	262.309 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1NC(=O)NC(=O)C1(CC)C=3C[C@H]2C[C@H](CC2)C=3;
	InChI InChI=1S/C14H18N2O3/c1-2-14(11(17)15-13(19)16-12(14)18)10-6-8-3-4-9(5-8)7-10/h6,8-9H,2-5,7H2,1H3,(H2,15,16,17,18,19)/t8-,9+/m0/s1 ; Key:MKELYWOVSPVORM-DTWKUNHWSA-N ;
	(what is this?) (verify)

Reposal is a barbiturate derivative invented in the 1960s in Denmark. It has sedative, hypnotic and anticonvulsant properties, and was used primarily for the treatment of insomnia.^[1]^[2]^[3]

^ Kessing SV, Tarding F, Thomsen AC (December 1963). "Reposal, A New Hypnotic. I. Pharmacodynamic Activity". Ugeskrift for Laeger (in Danish). 125: 1735–8. PMID 14103836.
^ Kessing SV, Tarding F, Thomsen AC (December 1963). "Reposal, A New Hypnotic. Ii. Clinical Effects". Ugeskrift for Laeger (in Danish). 125: 1739–41. PMID 14103837.
^ Nielsen P, Tarding F (1968). "The metabolic fate of 5-(bicyclo-3,2,1,-oct-2-en-2-yl)-5-ethyl barbituric acid, (Reposal)". Acta Pharmacologica et Toxicologica. 26 (6): 521–30. doi:10.1111/j.1600-0773.1968.tb00471.x. PMID 5756387.